A call for better information on care of adult cancer survivors for their primary care providers, and guidance on a form of breast lymphoma for which their are no guidelines. More »
Rituximab achieves prolonged progression-free survival for patients with chronic lymphocytic leukemia, but it boosts the risk of hepatitis B recurrence. More »
A black box warning has been added to the label of the commonly used anti-inflammatory drug rituximab warning that it may reactivate hepatitis B virus. More »
The FDA today advised physicians prescribing rituximab to screen and monitor all patients taking the drug for evidence of hepatitis B infection. More »
Gilead Sciences has submitted an NDA to the FDA for its new drug idelalisib, for the use in patients with indolent non-Hodgkin lymphoma that is refractory to rituximab and chemotherapy. More »
A 15-year prospective study shows that although cryoglobulinemic syndrome has no influence on overall survival of hepatitis C patients, it does influence the risk for other comorbidities. More »
Showing 1 - 6 of 667 results.